<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41912">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01974024</url>
  </required_header>
  <id_info>
    <org_study_id>GSNUH 2013-1</org_study_id>
    <nct_id>NCT01974024</nct_id>
  </id_info>
  <brief_title>Randomize Controlled Phase 3, Cross-over Trial of Dexamethasone-induced Hiccup in Chemotherapy Patients Treated by Methylprednisolone Rotation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung-Ang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chung-Ang University</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study were to investigate the feasibility of methylprednisolone rotation as
      treatment of DIH
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The intensities of hiccups</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinically assessed every cycles(2-4weeks). The intensities of hiccups were assessed using a NRS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The intensities of emesis</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>CLinically assessed every cycles (2-4weeks) The intensities of emesis were assessed using a NRS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Dexamethasone-induced Hiccup in Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone was replaced with methylprednisolone as an antiemetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone was re-administered in the cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all solid cancer patients on chemotherapy

          -  age &gt;18 years

          -  received dexamethasone as an antiemetic

        Exclusion Criteria:

          -  brain metastases

          -  hiccups before dexamethasone administration

          -  uncontrolled diabetes mellitus

          -  uncontrolled esophagitis or peptic ulcer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung Hun Kang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Gyeongsang National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung Hun Kang, M.D.</last_name>
    <phone>82-10-9344-0543</phone>
    <email>newatp@gnu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>In Gyu Hwang, M.D.</last_name>
    <phone>82-10-3566-9053</phone>
    <email>hematoonco@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Chiram-dong, Jinju-si</city>
        <state>Gyeongsangnam-do</state>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chungang University Hospital</name>
      <address>
        <city>Dongjak-gu</city>
        <state>Seoul</state>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>In Gyu Hwang, M.D.</last_name>
      <phone>+82-10-3566-9053</phone>
      <email>hematoonco@naver.com</email>
    </contact>
    <investigator>
      <last_name>In Gyu Hwang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 31, 2013</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung-Ang University</investigator_affiliation>
    <investigator_full_name>In Gyu Hwang</investigator_full_name>
    <investigator_title>In Gyu Hwang/Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Dexamethasone</keyword>
  <keyword>Hiccup</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Methylprednisolone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hiccup</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
